Accumulating evidence has demonstrated that the HSF1-regulated proteostatic capacity of cells is closely associated with cancer development, progression, and chemoresistance, leading to poor clinical outcomes in patients with cancer [12]. This evidence concerns the gene HSF1 and cancer.